Lipella Pharmaceuticals Inc. Operating Income
Lipella Pharmaceuticals Inc. (LIPO) reported Operating Income of -$1.27 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2025-11-14
- Lipella Pharmaceuticals Inc. operating income (loss) for the quarter ending 2025-09-30 was -$1.27M.
- Lipella Pharmaceuticals Inc. operating income (loss) for the quarter ending 2025-06-30 was -$1.36M.
- Lipella Pharmaceuticals Inc. operating income (loss) for the quarter ending 2025-03-31 was -$1.33M.
- Lipella Pharmaceuticals Inc. operating income (loss) for the quarter ending 2024-12-31 was -$1.45M.
- Lipella Pharmaceuticals Inc. operating income (loss) for fiscal 2024 was -$5.08M.
- Lipella Pharmaceuticals Inc. operating income (loss) for fiscal 2023 was -$4.75M.
- Lipella Pharmaceuticals Inc. operating income (loss) for fiscal 2022 was -$2.59M.
- Lipella Pharmaceuticals Inc. operating income (loss) for fiscal 2021 was -$1.92M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$1.27M 10-Q · filed 2025-11-14 | -$2.63M derived: sum of 2 quarters · filed 2025-11-14 | -$3.96M 10-Q · filed 2025-11-14 | -$5.41M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | -$1.36M 10-Q · filed 2025-08-14 | -$2.68M 10-Q · filed 2025-08-14 | -$4.14M derived: sum of 3 quarters · filed 2025-08-14 | -$5.60M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | -$1.33M 10-Q · filed 2025-05-14 | -$2.78M derived: sum of 2 quarters · filed 2025-05-14 | -$4.24M derived: sum of 3 quarters · filed 2025-11-14 | -$5.19M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.91M derived: sum of 2 quarters · filed 2025-11-14 | -$3.86M derived: sum of 3 quarters · filed 2025-11-14 | -$5.08M 10-K · filed 2025-03-28 |
| 2024-09-30 | -$1.46M 10-Q · filed 2025-11-14 | -$2.41M derived: sum of 2 quarters · filed 2025-11-14 | -$3.63M 10-Q · filed 2025-11-14 | -$4.36M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$952.19K 10-Q · filed 2025-08-14 | -$2.17M 10-Q · filed 2025-08-14 | -$2.90M derived: sum of 3 quarters · filed 2025-08-14 | -$4.26M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.22M 10-Q · filed 2025-05-14 | -$1.95M derived: sum of 2 quarters · filed 2025-05-14 | -$3.30M derived: sum of 3 quarters · filed 2025-05-14 | -$4.88M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$729.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.09M derived: sum of 2 quarters · filed 2025-03-28 | -$3.66M derived: sum of 3 quarters · filed 2025-03-28 | -$4.75M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.36M 10-Q · filed 2024-11-14 | -$2.93M derived: sum of 2 quarters · filed 2024-11-14 | -$4.02M 10-Q · filed 2024-11-14 | -$4.38M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$1.58M 10-Q · filed 2024-08-13 | -$2.66M 10-Q · filed 2024-08-13 | -$3.02M derived: sum of 3 quarters · filed 2024-08-13 | -$3.73M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$1.08M 10-Q · filed 2024-05-09 | -$1.44M derived: sum of 2 quarters · filed 2024-05-09 | -$2.16M derived: sum of 3 quarters · filed 2024-05-09 | -$2.94M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$359.26K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.07M derived: sum of 2 quarters · filed 2024-02-27 | -$1.85M derived: sum of 3 quarters · filed 2024-02-27 | -$2.59M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$712.64K 10-Q · filed 2023-11-14 | -$1.49M derived: sum of 2 quarters · filed 2023-11-14 | -$2.23M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$781.15K 10-Q · filed 2023-08-14 | -$1.52M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$736.66K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$1.92M 10-K · filed 2023-03-31 |